The Schall Law Firm is investigating Erasca, Inc. for potential securities law violations after the company disclosed a patent infringement claim from Revolution Medicines related to its ERAS-0015 drug. This disclosure led to a 48.3% drop in Erasca's stock price on April 28, 2026. The investigation is examining whether Erasca issued false or misleading statements or failed to disclose important information to investors. Shareholders who suffered losses are encouraged to contact the law firm to discuss their rights and possibly join a class action lawsuit.
Breckenridge Distillery, a subsidiary of Tilray Brands, won top awards at the San Francisco World Spirits Competition. Their Rum Cask Finish received the highest honor, Double Gold with 97 points, while their Honey Whiskey earned a Gold medal. These ...
The global laboratory equipment services market, valued at $28.94 billion in 2025, is projected to grow to $62.83 billion by 2035 at an 8% CAGR. Growth is fueled by increased R&D investments, stricter regulatory compliance, and expanding biopharma an...
Reklaim Credit Solutions, a credit rating agency for the state-regulated cannabis industry, announced that co-founders Sam Fensterstock and Bob McCarthy have taken on executive roles as Chief Revenue Officer and Chief Technology Officer, respectively...
SIM swapping scams involve criminals hijacking your phone number by transferring it to a SIM or eSIM they control, allowing access to your bank and credit accounts without physical access to your phone. Since 2022, over 5,000 cases have been reported...
TRADEMARK, a global experiential marketing agency, won the Bronze Eventex Award for its exceptional work on Adobe MAX 2025, a major creative industry conference. The award highlights TRADEMARK's skill in blending creative ambition with precise execut...
